💼 The facility will complement the biopharmaceutical research and development activities of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).
💰 The project has received federal and state funding and aligns with Delaware’s priority of economic growth in the biopharmaceutical industry.
💡 The SABRE Center will support research, development, pilot-scale production, and workforce training in biomanufacturing.
🌍 UD officials believe that the SABRE Center will enhance national competitiveness in advanced manufacturing and contribute to the local biotech community.
🏭 The facility will be designed as a cGMP environment and will train Delaware workers in manufacturing biopharmaceuticals.
💪 The SABRE Center aims to strengthen domestic manufacturing capacity and supply chains, focusing on collaboration between academia and the private and public sectors.
Introduction:
The University of Delaware has begun construction on the SABRE Center, a biomanufacturing facility that will support the biopharmaceutical industry in Delaware and the broader region. The center will provide resources for research, development, pilot-scale production, and workforce training in the field of biomanufacturing.
- The SABRE Center will be a pilot-scale biopharmaceutical manufacturing facility located next to the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) in Delaware.
- The center will complement the activities of NIIMBL and the biopharmaceutical industry in Delaware, supporting research, development, and workforce training.
- The project is supported by federal and state funding, aligning with Delaware’s priority of economic growth in the biopharmaceutical industry and the life sciences sector.
- The SABRE Center will focus on scaling up and maturing manufacturing innovations and technologies for biopharmaceutical medicines.
- The center aims to enhance national competitiveness in advanced manufacturing and establish a vibrant industrial ecosystem in the region.
Conclusion:
The construction of the SABRE Center at the University of Delaware marks an important step towards advancing biomanufacturing and supporting the biopharmaceutical industry in Delaware and the broader region. The center will provide resources for research, development, production, and workforce training, contributing to economic growth and competitiveness in the field of biopharmaceuticals. This project demonstrates the importance of collaboration between academia, the private sector, and the government in driving innovation and resilience in the face of public health threats.
